Drugs / UCPVax
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02818426 | Apr 2016 → Aug 2022 | non-small cell lung carcinoma | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07347210 | Jan 2026 → Jan 2029 expected | glioblastoma | Centre Hospitalier Universitaire de Besancon | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05528952 | Sep 2022 → Mar 2028 expected | hepatocellular carcinoma | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2 | NCT04263051 | Sep 2020 → Nov 2023 | non-small cell lung carcinoma | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2 | NCT04280848 | May 2020 → Dec 2023 | glioblastoma | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2 | NCT03946358 | Feb 2020 → Mar 2024 | anal canal cancer, cervical cancer, head and neck squamous cell carcinoma | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCPVAx | “UCPVAx is a therapeutic vaccine based on the telomerase-derived UCP designed to induce strong TH1 CD4 T cell responses in cancer patients.” NCT02818426 ↗ |
| Known as | Universal cancer peptide-based vaccine | “Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase.” PMID 36070539 ↗ Sep 2022 |
| Modality | Vaccine | “UCPVax, a CD4 helper peptide vaccine” PMID 40543509 ↗ Jun 2025 |
| Route | Subcutaneous | “injected subcutaneously” NCT02818426 ↗ |